ReviewJournal of Korean medical science2025
Injection-Based Therapies for Migraine in Older Adults: A Narrative Review of OnabotulinumtoxinA, Greater Occipital Nerve Block, and Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies.
Review in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world effectiveness and safety of CGRP monoclonal antibodies in elderly migraine patients: a Korean multicenter study.The journal of headache and pain · 2026Article
- Geriatric Migraine, Geroscience, and Sustainable Development Goals: Bridging Clinical Complexity and Public Health Priorities.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As global populations age, the clinical approach to managing migraine must evolve. Migraine in older adults presents unique treatment challenges due to comorbidities, poor adherence to treatment, altered pharmacokinetics, and polypharmacy. Injection -based preventive treatments such as onabotulinumtoxinA (BoNT-A), greater occipital nerve blocks (GONB), and anti-calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) offer promising alternatives. This narrative review highlights the underrepresentation of older adults in migraine clinical trials and summarizes the effectiveness and safety of BoNT-A, GONB, and CGRP mAbs in patients over 65 years of age. To identify relevant studies addressing migraine management in the older adults, we conducted a comprehensive literature search of PubMed, Embase, and Cochrane Library. The search was limited from the past ten years, up to 5 April 2025. Studies were included if clinical trial, observational, real-world data, or review examined migraine treatment in adults over 65 years, with separate data according to age. A total of 22 studies were included: 4 on BoNT-A, 2 on GONB, 13 on anti-CGRP mAbs, and 3 reviews on injectable therapies. BoNT-A has shown significant benefits in reducing migraine frequency, acute medication use, and disability in real-world settings though randomized trials did not include older adults. GONB has demonstrated high response rates in older adults, although there was no separate analysis for patients over 65 years of age in randomized controlled trials. In contrast, CGRP mAbs have increasingly included in trials, with some trials enrolling patients up to 75 years. Subgroup analyses and real-world data support their comparable effectiveness and safety in older adults. BoNT-A, GONB and CGRP mAbs show effectiveness and are well tolerated for migraine prevention in older adults. Given the growing ageing population and their unique therapeutic needs, proactive migraine management in older migraine patients with injection-based and oral preventive is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.